Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
Cet article présente une mise à jour des recommandations de l'"American Society of Clinical Oncology" concernant l'utilisation de tests de recherche de mutations au niveau du gène ESR1 pour orienter la stratégie thérapeutique chez les patientes atteintes d'un cancer du sein métastatique HR+ HER2-
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).
Journal of Clinical Oncology , article en libre accès, 2022